相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms
Karlo Huenerbein et al.
ANNALS OF HEMATOLOGY (2021)
A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms
Eva N. Hamulyak et al.
BLOOD ADVANCES (2021)
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
Nigel S. Key et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial
Robert D. McBane et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis
Lukas Ronner et al.
BLOOD (2020)
Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm-associated venous thromboembolism in a large tertiary centre in the UK
Natalia Curto-Garcia et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A multicenter real-life study on anticoagulant treatment with direct oral anticoagulants in patients withPh negative myeloproliferative neoplasms
Alessandra Serrao et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Direct Oral Anticoagulants for Myeloproliferative Neoplasms (MPN-DOACs): Results from an International Study on 442 Patients
Tiziano Barbui et al.
BLOOD (2020)
High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation
Kai Wille et al.
ANNALS OF HEMATOLOGY (2019)
Vascular endothelial cell expression of JAK2(V617F) is sufficient to promote a pro-thrombotic state due to increased P-selectin expression
Alexandre Guy et al.
HAEMATOLOGICA (2019)
A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms
Tarinee Rungjirajittranon et al.
BMC CANCER (2019)
Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper
Tiziano Barbui et al.
BLOOD CANCER JOURNAL (2019)
Direct Oral Anticoagulants for Prevention of Recurrent Thrombosis in Myeloproliferative Neoplasms
Kateryna Fedorov et al.
BLOOD (2019)
Risk of Hemorrhage in Patients with Polycythemia Vera Exposed to Aspirin in Combination with Anticoagulants: Results of a Prospective, Multicenter, Observational Cohort Study (REVEAL)
Jeffrey I. Zwicker et al.
BLOOD (2019)
Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis
Alessandra Carobbio et al.
BLOOD ADVANCES (2019)
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
Annie M. Young et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH
A. A. Khorana et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Tiziano Barbuil et al.
LEUKEMIA (2018)
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Gary E. Raskob et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms
Ofir Wolach et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Essential thrombocythemia treatment algorithm 2018
Ayalew Tefferi et al.
BLOOD CANCER JOURNAL (2018)
Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018
Guido Finazzi et al.
BLOOD CANCER JOURNAL (2018)
Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms
Valerio De Stefano et al.
BLOOD CANCER JOURNAL (2018)
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms
Valerio De Stefano et al.
BLOOD CANCER JOURNAL (2018)
Polycythemia vera treatment algorithm 2018
Ayalew Tefferi et al.
BLOOD CANCER JOURNAL (2018)
Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms RESPONSE
Malin Hultcrantz et al.
ANNALS OF INTERNAL MEDICINE (2018)
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study
Noemie Kraaijpoel et al.
THROMBOSIS AND HAEMOSTASIS (2018)
Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: The Mayo clinic experience with 84 consecutive cases
Sravanthi Lavu et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Neutrophil extracellular traps in immunity and disease
Venizelos Papayannopoulos
NATURE REVIEWS IMMUNOLOGY (2018)
Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis
Andrea De Gottardi et al.
LIVER INTERNATIONAL (2017)
Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera
A. Rottenstreich et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2017)
Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms
Jean-Christophe Ianotto et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2017)
Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
Federico Lussana et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Risk of Arterial Thromboembolism in Patients With Cancer
Babak B. Navi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
J. I. Weitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Benefits and Risks of Antithrombotic Therapy in Essential Thrombocythemia A Systematic Review
Derek K. Chu et al.
ANNALS OF INTERNAL MEDICINE (2017)
Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease
Joan How et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2017)
Antithrombotic Therapy for VTE Disease CHEST Guideline and Expert Panel Report
Clive Kearon et al.
CHEST (2016)
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation
Alberto Alvarez-Larran et al.
HAEMATOLOGICA (2016)
Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
A. Kaifie et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists
V. De Stefano et al.
LEUKEMIA (2016)
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients
V. De Stefano et al.
BLOOD CANCER JOURNAL (2016)
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation
Alberto Alvarez-Larran et al.
HAEMATOLOGICA (2016)
Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia
Juan-Carlos Hernandez-Boluda et al.
ANNALS OF HEMATOLOGY (2015)
Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort
Elizabeth M. Kander et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2015)
Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study
Malin Hultcrantz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Epidemiology of venous thromboembolism
John A. Heit
NATURE REVIEWS CARDIOLOGY (2015)
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
T. Barbui et al.
BLOOD CANCER JOURNAL (2015)
Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms An European Leukemia Net study
Ida Martinelli et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
Elisa Rumi et al.
BLOOD (2014)
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
Raajit Rampal et al.
BLOOD (2014)
Epidemiology of myeloproliferative neoplasms in the United States
Jyotsna Mehta et al.
LEUKEMIA & LYMPHOMA (2014)
Treatment of thromboembolic events coincident with the diagnosis of myeloproliferative neoplasms: A physician survey
Martin H. Ellis et al.
THROMBOSIS RESEARCH (2014)
Cerebral venous thrombosis and myeloproliferative neoplasms: Results from two large databases
Francesco Dentali et al.
THROMBOSIS RESEARCH (2014)
Hematocrit and flow rate regulate the adhesion of platelets to von Willebrand factor
Hsieh Chen et al.
BIOMICROFLUIDICS (2013)
JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway
Maria De Grandis et al.
BLOOD (2013)
JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia
Catherine M. Hobbs et al.
BLOOD (2013)
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
A. Tefferi et al.
LEUKEMIA (2013)
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Roberto Marchioli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Apixaban for Extended Treatment of Venous Thromboembolism
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: A role for the JAK2 V617F mutation re-evaluation
Donatella Colaizzo et al.
THROMBOSIS RESEARCH (2013)
Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis
Jasper H. Smalberg et al.
BLOOD (2012)
Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort
Peter J. Campbell et al.
BLOOD (2012)
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
Tiziano Barbui et al.
BLOOD (2012)
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
Alessandra Carobbio et al.
BLOOD (2011)
Endothelial progenitor cells are clonal and exhibit the JAK2V617F mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms
Luciana Teofili et al.
BLOOD (2011)
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3
Tiziano Barbui et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: Relationship with thrombosis occurrence and JAK2 V617F allele burden
Eduardo Arellano-Rodrigo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?
Tiziano Barbui et al.
BLOOD (2009)
The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome
Selcuk Sozer et al.
BLOOD (2009)
Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia
Issa J. Dahabreh et al.
LEUKEMIA RESEARCH (2009)
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments
Valerio De Stefano et al.
HAEMATOLOGICA (2008)
Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin α5 chain and Lu/BCAM
Marie-Paule Wautier et al.
BLOOD (2007)
Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V617F status, clonality, and antiphospholipid antibodies
B. Robertson et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera
Raffaele Landolfi et al.
BLOOD (2007)
Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: Therapeutic implications
JJ Michiels et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2006)
Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution
F Cervantes et al.
LEUKEMIA (2006)
Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera
A Falanga et al.
EXPERIMENTAL HEMATOLOGY (2005)
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
R Marchioli et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Malignancies, prothrombotic mutations, and the risk of venous thrombosis
JW Blom et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Efficacy and safety of low-dose aspirin in polycythemia vera
R Landolfi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
分享论文
